Table 2 Demographics and baseline characteristics
Parameter | sCAP patients (phase II CIGMA) N = 160 | Healthy subjects (phase I) N = 24 | p-valuea | |
|---|---|---|---|---|
Male, n (%) | n/a | 113 (70.6) | 10 (41.7) | n/d |
Race, n (%) | ||||
Caucasian | n/a | 154 (96.3) | 22 (91.7) | n/d |
African | 4 (2.5) | 0 | ||
Asian | 1 (0.6) | 2 (8.3) | ||
Other (Latin/Hispanic) | 1 (0.6) | 0 | ||
Country, n (%) | ||||
Germany | n/a | 38 (23.8) | 24 (100) | n/d |
Spain | 108 (67.5) | 0 | ||
UK | 14 (8.8) | 0 | ||
Age (years), mean (SD) | n/a | 65 (15) | 30 (7) | n/d |
BMI (kg/m2), mean (SD) | n/a | 26.2 (4.9) | 23.6 (3.2) | n/d |
IgM (g/L) | ||||
n | 0.4–2.3 [41] | 160 | 24 | < 0.001 |
Median (IQR) | 0.57 (0.38–0.88) | 1.0 (0.8–1.4) | ||
IgG (g/L) | ||||
n | 7–16 [41] | 160 | 24 | < 0.001 |
Median (IQR) | 6.6 (4.6–8.7) | 9.9 (8.5–12.4) | ||
IgA (g/L) | ||||
n | 0.7–4.0 [41] | 160 | 24 | 0.360 |
Median (IQR) | 2.1 (1.4–3.2) | 2.0 (1.6–2.5) | ||
Neutrophils (109/L) | ||||
n | 2.5–8.0 [37] | 150 | 24 | < 0.001 |
Median (IQR) | 11.5 (6.0–17.1) | 3.7 (3.2–4.7) | ||
Lymphocytes (109/L) | ||||
n | 1.0–4.0 [37] | 150 | 24 | < 0.001 |
Median (IQR) | 0.69 (0.42–1.0) | 1.6 (1.3–2.3) | ||
NLR | ||||
n | 0.8–3.5 [42] | 149 | 24 | < 0.001 |
Median (IQR) | 16.1 (8.3–27.3) | 2.1 (1.5–3.1) | ||
Monocytes (109/L) | ||||
n | 0.1–0.7 [37] | 155 | 24 | 0.468 |
Median (IQR) | 0.51 (0.23–0.90) | 0.44 (0.35–0.56) | ||
Platelets (109/L) | ||||
n | 150–450[[43]] | 160 | 24 | 0.516 |
Median (IQR) | 202 (149–277) | 225 (182–259) | ||
CRP (mg/L) | ||||
n | 0–10 [40] | 155 | 24 | < 0.001 |
Median (IQR) | 230 (113–333) | 0.1 (0.1–0.2) | ||
PCT (µg/L) | ||||
n | ≤ 0.10 [39] | 145 | n/d | n/d |
Median (IQR) | 5.1 (0.91–20.5) | |||
Albumin (g/L) | ||||
n | 35–55 [43] | 125 | 24 | < 0.001 |
Median (IQR) | 27.0 (24.1–31.0) | 47.0 (46.0–50.0) | ||